SAN DIEGO, CA and VANCOUVER, Oct. 2, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS), a urology company developing a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present at the 11th Annual BIO Investor Forum in San Francisco. Mr. Woods' presentation will take place at 4:00 p.m. PDT on Tuesday, October 9, 2012.
A live webcast of the presentation may be accessed via the Sophiris website at www.sophirisbio.com. A replay of the presentation will be available on the company's website for 90 days.
About Sophiris Bio:
Sophiris Bio Inc. is a urology company developing a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), an unsatisfied market with large potential demand. PRX302, the company's lead candidate for BPH, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is advised by world-leading urologists, backed by experienced investors, and led by a team that has achieved more than twenty drug approvals including several drugs with annual sales in excess of $1 billion. For more information, please visit www.sophirisbio.com.
Certain statements included in this press release may be considered forward-looking, including statements about the potential for PRX302. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris Bio's' current beliefs as well as assumptions made by and information currently available to Sophiris Bio and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties inherent in late stage drug development and risks relating to obtaining FDA and other regulatory approvals as well as risks identified by Sophiris Bio in its public securities filings; actual events may differ materially from current expectations. Sophiris Bio disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Sophiris Bio, Inc.